Cardiovascular Safety Profile of Combretastatin A4 Phosphate in a Single-Dose Phase I Study in Patients with Advanced Cancer

Clinical Cancer Research

Volumn 10, Issue 1 I, 2004, Pages 96-100

  Cooney, Matthew M ^a,b   Radivoyevitch, Tomas ^a   Dowlati, Afshin ^a,b   Overmoyer, Beth ^a,b   Levitan, Nathan ^a,b   Robertson, Kelly ^b   Levine, Sandra L ^b   DeCaro, Kathleen ^b   Buchter, Carol ^c   Taylor, Anne ^d   Stambler, Bruce S ^b   Remick, Scot C ^a,b  

^a CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

^c UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; COMBRETASTATIN A4 PHOSPHATE; PLANT EXTRACT;

ABDOMINAL CRAMP; ADULT; ADVANCED CANCER; AGED; ALOPECIA; AREA UNDER THE CURVE; ARTICLE; BLOOD PRESSURE MEASUREMENT; BLOOD PRESSURE MONITORING; BONE MARROW SUPPRESSION; CANCER PAIN; CARDIOTOXICITY; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RESPONSE; CLINICAL ARTICLE; CLINICAL PROTOCOL; CLINICAL TRIAL; CORONARY ARTERY DISEASE; CORONARY ARTERY OBSTRUCTION; CORRELATION COEFFICIENT; DOSE RESPONSE; DRUG DOSE REGIMEN; DRUG INFUSION; DRUG SAFETY; DRUG SCREENING; ELECTROCARDIOGRAM; FEMALE; FLUSHING; HEADACHE; HEART RATE; HEART VENTRICLE ARRHYTHMIA; HOT FLUSH; HUMAN; LEFT ANTERIOR DESCENDING CORONARY ARTERY; MALE; PATIENT SELECTION; PHARMACODYNAMICS; PHASE 1 CLINICAL TRIAL; PRACTICE GUIDELINE; PRIORITY JOURNAL; PULSE RATE; QT INTERVAL; QT PROLONGATION; RISK FACTOR; RR INTERVAL; SIDE EFFECT; SINGLE DRUG DOSE; ST SEGMENT DEPRESSION; ST SEGMENT ELEVATION; STOMATITIS;

ADULT; AGED; ANTINEOPLASTIC AGENTS, PHYTOGENIC; BLOOD PRESSURE; CARDIOVASCULAR SYSTEM; CORONARY DISEASE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; ELECTROCARDIOGRAPHY; FEMALE; HEART RATE; HUMANS; INFUSIONS, INTRAVENOUS; MALE; MIDDLE AGED; NEOPLASMS; SAFETY; STILBENES;

EID: 1642494772     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-0364-3     Document Type: Article

References (11)

1. Pettit, G. R., Cragg, G. M., Herald, D. L., Schmidt, J. M., and Lohavanijaya, P. Isolation and structure of combretastatin. Can. J. Chem., 60: 1374-1376, 1982.
2. Dark, G. G., Hill, S. A., Prise, V. E., Tozer, G. M., Pettit, G. R., and Chaplin, D. J. Combretastatin A-4, an agent that displays potent and selective toxicity toward tumor vasculature. Cancer Res., 57: 1829-1834, 1997.
3. Tozer, G. M., Prise, V. E., Wilson, J., Locke, R. J., Vojnovic, B., Stratford, M. R. L., Dennis, M. F., and Chaplin, D. J. Combretastatin A-4 phosphate as tumor vascular-targeting agent: early effects in tumors and normal tissues. Cancer Res., 59: 1626-1634, 1999.
4. Dowlati, A., Robertson, K., Cooney, M., Petros, W. P., Stratford, M., Jesberger, J., Rafie, N., Overmoyer, B., Makkar, V., Stambler, B., Taylor, A., Waas, J., Lewin, J., McCrae, K., and Remick, S. C. A Phase I pharmacokinetic and translational study of the novel vascular targeting agent combretastatin A4 phosphate on a single-dose intravenous schedule in patients with advanced cancer. Cancer Res., 62: 3408-3416, 2002.
5. Ohnishi, K., Yoshida, H., Shigeno, K., Nakamura, S., Fujisawa, S., Naito, K., Shinjo, K., Fujita, Y., Matsui, H., Takeshita, A., Sugiyana, S., Satoh, H., Tedra, H., and Ohno, R. Prolongation of the QT interval and ventricular tachycardia in patients treated with arsenic trioxide for acute promyelocytic leukemia. Ann. Intern. Med., 133: 881-885, 2000.
6. Trump, D. L., Tutsch, K. D., Willson, J. K. V., Remick, S. C., Simon, K., Alberti, D. B., Grem, J. L., Keller, J., and Tormey, D. C. Phase I clinical trial and pharmacokinetic evaluation of acodazole (NSC 305884), an imidazoquinoline derivative with electrophysiological effects on the heart. Cancer Res., 47: 3895-3900, 1987.
7. National Cancer Institute: Common Toxicity Criteria Version 2.0. Bethesda, MD, National Cancer Institute, 1998.
8. Saige, A., Larson, M. G., Gobdberg, R. J., Bengtson, J. R., and Levy, D. An improved method for adjusting the QT interval for heart rate (the Framingham Heart Study.) Am. J. Cardiol., 70: 797-801, 1992.
9. + channel blocker isolated from 'hiccup nut' toxin. NeuroReport, 7: 2575-2579. 1996.
10. Stevenson, J. P., Gallagher, M., Sun, W., Algazy, K., Vaughn, D. J., Hallen, D. G., et al. Phase I/pharmacokinetic trial of the endothelial toxin combretastatin A4P (CA4P) administered as an IV bolus on a daily × 5 schedule every 21 days. Proc. Am. Assoc. Cancer Res., 41: 544, 2000.
11. Rustin, G. J., Price, P., Stratford, M., Galbraith, S., Anderson, H., Folkes, L., et al. Phase I study of weekly intravenous combretastatin A-4 phosphate (CA4P): pharmacokinetics and toxicity. Proc. Am. Soc. Clin. Oncol., 20: 99a, 2001.